Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Chronic Myeloid Leukemia – Current Treatment – Treatment Sequencing – Chronic Myeloid Leukemia (US)
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting Drill down into physicians’ treatment sequences and understand whom to position…
Non-Hodgkin’s Lymphoma – Unmet Need – Detailed, Expanded Analysis: Relapsed or Refractory DLBCL (US/EU)
Relapsed / refractory diffuse large B-cell lymphoma (R/R DLBCL) is an aggressive disease with significant unmet need. The treatment landscape has evolved since the approval of various novel…
Immune Thrombocytopenic Purpura | Treatment Algorithms: Claims Data Analysis | US | 2023
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that leads to a decrease in platelet production, thus increasing the risk of bleeding. Current therapies for ITP can be broadly…
Myelodysplastic Syndromes – Unmet need – Unmet Need – Myelodysplastic Syndromes (US/EU)
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem-cell disorders that disrupt normal hematopoiesis in the bone marrow. All pharmacological approaches to treating…
Acute Myeloid Leukemia – Unmet Need – Unmet Need – First-Line Intensive-Induction-Eligible Acute Myeloid Leukemia (US/EU)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, originating from mutant myeloid precursor cells. Presently, the AML drug market is dominated by chemotherapy backbones, but…
